Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer
Huebner N. A., Shariat Sh.
European Urology
Vol.77, Issue1, P. 132-133
Опубликовано: 2020
Тип ресурса: Комментарий
DOI:10.1016/j.eururo.2019.08.029
Аннотация:
[краткое описание не найдено]
Ключевые слова:
abiraterone; apalutamide; docetaxel; enzalutamide; prostate specific antigen; enzalutamide; phenylthiohydantoin; androgen deprivation therapy; cancer combination chemotherapy; cancer fatigue; cancer localization; cancer risk; cancer survival; cancer therapy; clinical decision making; clinical practice; cost effectiveness analysis; disease burden; follow up; health care quality; human; local therapy; male; metastasis; Note; overall survival; patient selection; priority journal; progression free survival; prostate cancer; seizure; prostate tumor; Humans; Male; Phenylthiohydantoin; Prostatic Neoplasms
Язык текста: Английский
ISSN: 1873-7560
Huebner N. A.
Shariat Sh. Sharokh 1973-
Хуебнер Н. А.
Шариат Ш. Шарох 1973-
Re: Enzalutamide with Standard First-line Therapy in Metastatic Prostate Cancer
Текст визуальный непосредственный
European Urology
Elsevier Science Publisher B.V.
Vol.77, Issue1 P. 132-133
2020
Комментарий
abiraterone apalutamide docetaxel enzalutamide prostate specific antigen enzalutamide phenylthiohydantoin androgen deprivation therapy cancer combination chemotherapy cancer fatigue cancer localization cancer risk cancer survival cancer therapy clinical decision making clinical practice cost effectiveness analysis disease burden follow up health care quality human local therapy male metastasis Note overall survival patient selection priority journal progression free survival prostate cancer seizure prostate tumor Humans Male Phenylthiohydantoin Prostatic Neoplasms
[краткое описание не найдено]